MX2007001876A - Antagonistas de antigeno muy tardio-4. - Google Patents
Antagonistas de antigeno muy tardio-4.Info
- Publication number
- MX2007001876A MX2007001876A MX2007001876A MX2007001876A MX2007001876A MX 2007001876 A MX2007001876 A MX 2007001876A MX 2007001876 A MX2007001876 A MX 2007001876A MX 2007001876 A MX2007001876 A MX 2007001876A MX 2007001876 A MX2007001876 A MX 2007001876A
- Authority
- MX
- Mexico
- Prior art keywords
- vla
- antagonists
- compounds
- cell
- adhesion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Abstract
Los compuestos de formula (I) son antagonistas de VLA-4, y como tal son utiles en la inhibicion o prevencion de la adhesion celular y las patologias mediadas por adhesion celular; estos compuestos se pueden formular hacia composiciones farmaceuticas y son adecuados para uso en el tratamiento de la enfermedad de intestino infamatorio incluyendo colitis ulcerativa y enfermedad de Crohn, esclerosis multiple, asma, y artritis reumatoide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60194204P | 2004-08-16 | 2004-08-16 | |
PCT/US2005/028768 WO2006023396A2 (en) | 2004-08-16 | 2005-08-12 | Vla-4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007001876A true MX2007001876A (es) | 2007-05-09 |
Family
ID=35502447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007001876A MX2007001876A (es) | 2004-08-16 | 2005-08-12 | Antagonistas de antigeno muy tardio-4. |
Country Status (15)
Country | Link |
---|---|
US (1) | US7776891B2 (es) |
EP (1) | EP1781686B1 (es) |
JP (1) | JP4649476B2 (es) |
KR (1) | KR20070044054A (es) |
CN (1) | CN101006097B (es) |
AT (1) | ATE430761T1 (es) |
AU (1) | AU2005277634B2 (es) |
BR (1) | BRPI0514415A (es) |
CA (1) | CA2576647C (es) |
DE (1) | DE602005014364D1 (es) |
IL (1) | IL181267A0 (es) |
MX (1) | MX2007001876A (es) |
NO (1) | NO20071399L (es) |
RU (1) | RU2007109601A (es) |
WO (1) | WO2006023396A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101163472A (zh) * | 2005-04-21 | 2008-04-16 | 默克公司 | Vla-4拮抗剂 |
CA2707360A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
WO2017173302A2 (en) * | 2016-04-01 | 2017-10-05 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
MX2021005050A (es) | 2018-10-30 | 2021-06-15 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de integrina alfa4beta7. |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体 |
JP2022543465A (ja) | 2019-08-14 | 2022-10-12 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291511B1 (en) * | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6903075B1 (en) * | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
US6455550B1 (en) * | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6338084B1 (en) * | 1998-12-17 | 2002-01-08 | International Business Machines Corporation | Method for process-specific exchange of data between machines in a network |
TR200102399T2 (tr) * | 1999-02-18 | 2002-01-21 | F. Hoffmann-La Roch Ag | Tiyoamid türevleri |
MXPA01013406A (es) * | 1999-06-30 | 2003-09-04 | Daiichi Seiyaku Co | Compuestos inhibidores de vla-4. |
DE60033684T2 (de) * | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
CN1196682C (zh) * | 1999-12-06 | 2005-04-13 | 霍夫曼-拉罗奇有限公司 | 4-吡啶基-n-酰基-l-苯丙氨酸 |
CZ303435B6 (cs) * | 1999-12-06 | 2012-09-12 | F. Hoffmann-La Roche Ag | 4-Pyrimidinyl-N-acyl-1-fenylalanin, meziprodukt pro jeho prípravu a farmaceutická kompozice |
US6559174B2 (en) * | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
US6855708B2 (en) * | 2001-03-20 | 2005-02-15 | Merck & Co., Inc. | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors |
JP2004526733A (ja) * | 2001-03-20 | 2004-09-02 | メルク エンド カムパニー インコーポレーテッド | 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体 |
TW200307671A (en) * | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
EP1725542A1 (en) * | 2004-03-10 | 2006-11-29 | Merck & Co., Inc. | Vla-4 antagonists |
-
2005
- 2005-08-12 MX MX2007001876A patent/MX2007001876A/es unknown
- 2005-08-12 WO PCT/US2005/028768 patent/WO2006023396A2/en active Application Filing
- 2005-08-12 JP JP2007527893A patent/JP4649476B2/ja not_active Expired - Fee Related
- 2005-08-12 DE DE602005014364T patent/DE602005014364D1/de active Active
- 2005-08-12 CA CA2576647A patent/CA2576647C/en not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514415-9A patent/BRPI0514415A/pt not_active Application Discontinuation
- 2005-08-12 CN CN2005800277189A patent/CN101006097B/zh not_active Expired - Fee Related
- 2005-08-12 KR KR1020077006034A patent/KR20070044054A/ko not_active Application Discontinuation
- 2005-08-12 US US11/659,608 patent/US7776891B2/en active Active
- 2005-08-12 EP EP05808535A patent/EP1781686B1/en not_active Not-in-force
- 2005-08-12 AU AU2005277634A patent/AU2005277634B2/en not_active Ceased
- 2005-08-12 RU RU2007109601/04A patent/RU2007109601A/ru not_active Application Discontinuation
- 2005-08-12 AT AT05808535T patent/ATE430761T1/de not_active IP Right Cessation
-
2007
- 2007-02-11 IL IL181267A patent/IL181267A0/en unknown
- 2007-03-15 NO NO20071399A patent/NO20071399L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005277634B2 (en) | 2011-02-17 |
CA2576647A1 (en) | 2006-03-02 |
NO20071399L (no) | 2007-05-08 |
WO2006023396A3 (en) | 2006-04-27 |
CN101006097B (zh) | 2012-07-11 |
EP1781686A2 (en) | 2007-05-09 |
US7776891B2 (en) | 2010-08-17 |
WO2006023396A2 (en) | 2006-03-02 |
KR20070044054A (ko) | 2007-04-26 |
RU2007109601A (ru) | 2008-09-27 |
BRPI0514415A (pt) | 2008-06-10 |
AU2005277634A1 (en) | 2006-03-02 |
CN101006097A (zh) | 2007-07-25 |
IL181267A0 (en) | 2007-07-04 |
JP2008510005A (ja) | 2008-04-03 |
CA2576647C (en) | 2011-12-13 |
ATE430761T1 (de) | 2009-05-15 |
EP1781686B1 (en) | 2009-05-06 |
JP4649476B2 (ja) | 2011-03-09 |
DE602005014364D1 (de) | 2009-06-18 |
US20070219252A1 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007001876A (es) | Antagonistas de antigeno muy tardio-4. | |
GB0625648D0 (en) | Compounds | |
GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
SG170024A1 (en) | Imidazole-based compounds, compositions comprising them and methods of their use | |
IN2012DN01233A (es) | ||
PT1902037E (pt) | 2,4-diamino-pirimidinas como inibidores de aurora | |
WO2008011392A3 (en) | Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation | |
MX2010003612A (es) | Derivados de oxadiazol. | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
MX2010001733A (es) | Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. | |
MX2007003175A (es) | Medicamentos que contienen compuestos de carbonilo y su uso. | |
MX2009004707A (es) | Piridina carboxamides como inhibidores 11-beta-hsd1. | |
JO3640B1 (ar) | استخدام مركبات البوليول للحصول على انواع ذات اشكال متعددة ثابتة من الريفاكسيمين | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
UA103181C2 (ru) | Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент | |
UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
TW200745122A (en) | New compounds I | |
MX2011010451A (es) | Derivados de oxadiazol. | |
WO2008045564A3 (en) | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor | |
TW200736227A (en) | New compounds III | |
SG158091A1 (en) | Imidazoazepinone compounds | |
HRP20080452T3 (en) | Orally disintegrating pharmaceutical composition comprising risperidone | |
TW200745133A (en) | New compounds II |